A new FDA Fast Track designation for Zambon
Zambon, a multinational pharmaceutical company that focuses on innovation and development with the aim to improve the quality of people’s health and patients’ lives, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Liposomal Cyclosporine A for Inhalation (L‑CsA‑i), in late-stage clinical development for the treatment of Bronchiolitis Obliterans Syndrome (BOS). L‑CsA‑i, developed by Breath Therapeutics which was acquired by Zambon in 2019, previously received orphan drug designation from the FDA and European Medicines Agency for the treatment of BOS.
“Zambon is committed to its mission of innovating cure and improving the quality of life for people living with severe respiratory diseases worldwide. The FDA’s Fast Track designation for L‑CsA‑i represents an important recognition of its potential to address the unmet medical need of patients with BOS, a devastating rare disease with currently no approved treatment,” said Roberto Tascione, Zambon’s CEO.
The FDA Fast Track program facilitates the development and review of potential new drugs intended to treat serious conditions with unmet medical need, allowing important new drugs, if requisite criteria are met, to become more quickly available to people suffering from serious conditions.
“We believe Fast Track designation provides an opportunity for frequent interactions with the FDA which may potentially expedite the development and registration of L‑CsA‑i,” said Paola Castellani, CMO at Zambon. “We will work closely with the FDA to advance the BOSTON clinical program and accelerate our efforts to develop an effective therapy for the treatment of BOS.”
Fast Track Designation may allow a therapy to be eligible for several benefits including enhanced interaction with the FDA and the potential for Accelerated Approval and Priority Review at the time of a New Drug Application (NDA) filing, if relevant criteria are met. Additional information about FDA Fast Track designation is available at https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/fast-track.
Bronchiolitis Obliterans Syndrome (BOS)
Bronchiolitis Obliterans Syndrome (BOS), also known as obliterative bronchiolitis (OB), is caused by T‑cell mediated inflammation that leads to blockage of bronchioles, the small and medium airways in the lungs, resulting in respiratory failure and death. BOS most commonly affects people who have received lung transplant or allogeneic hematopoietic stem cell transplant (alloHSCT), although it is also associated with autoimmune disease and exposure to environmental contaminants. Based on 2019 company market research, an estimated 30,000 lung transplant and alloHSCT recipients worldwide are affected by BOS.
Liposomal Cyclosporine A for Inhalation (L-CsA-i)
Liposomal Cyclosporine A for Inhalation (L-CsA-i) is a novel liposomal formulation of cyclosporine A developed for inhaled delivery to the lungs. Calcineurin inhibitors (CNIs), like cyclosporine A, are highly potent immunosuppressive drugs and a cornerstone of lung transplant medicine. L‑CsA‑i is administered via a drug-specific Investigational eFlow® Technology nebulizer system (PARI Pharma GmbH). The investigational drug-device combination is designed to deliver L‑CsA‑i to the site of disease in the lung.
BOSTON Clinical Development Program
L-CsA-i is being evaluated for the treatment of BOS in patients age six and older. Five clinical trials are currently ongoing or planned. BOSTON-1 and BOSTON-2 are pivotal Phase 3 studies of adults with BOS following lung transplantation. BOSTON-3 is an open-label extension study for eligible study participants who complete BOSTON-1 or BOSTON-2. BOSTON-4 is a safety and exploratory efficacy study and is the first trial of L‑CsA‑i in adults with BOS following allogeneic hematopoietic stem cell transplant. BOSTON-5 is a planned safety study in pediatric patients with BOS.
About Zambon S.p.A.
Zambon is a multinational pharmaceutical company that focuses on innovation and development with the aim to improve patients’ lives. Based on a valuable heritage and strongly focused on the future, its goal is to improve people’s health through the development of innovative and quality healthcare solutions.
Zambon products are commercialized in 87 countries. The company has 20 subsidiaries in three different continents – Europe, America and Asia – and owns manufacturing units in Italy, Switzerland, China and Brazil. The company today has a strong focus on the treatment of rare diseases and specialties, on top of respiratory, pain management and women’s care. Zambon was established in 1906 in Italy and today counts 2,500 employees all over the world. For further information, please visit www.zambon.com
About Breath Therapeutics, a Zambon company
Founded in 2016, Breath Therapeutics is a biopharmaceutical company specializing in advanced inhaled therapeutics for severe respiratory diseases with high unmet medical need. The company’s proprietary drug formulations have been specifically designed for inhaled administration with exclusively licensed, high performance nebulizer technology. L‑CsA‑i is advancing in clinical trials as the first potential therapy for BOS, a rare and devastating lung disease with no currently approved treatments. In July 2019, Breath Therapeutics was acquired by Zambon. Please visit www.breath-therapeutics.com.
L-CsA-i and the eFlow® for L-CsA-i are investigational and their safety and efficacy have not been established for the uses described here.
For more information, please contact:
Global Head of Pharma Communication
Breath Therapeutics, a Zambon company
VP, Corporate Communications
FTI Consulting (media relations)
Victoria Foster Mitchell/Sam Purewal
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Optimized Dynamic Pricing by Pricefx Now an SAP Endorsed App3.6.2020 10:30:00 EEST | Press release
Pricefx, the global leader in native cloud pricing software, today announced that its Optimized Dynamic Pricing (ODP) solution is now an SAP endorsed app, available for online purchase on SAP® App Center. SAP Endorsed Apps are a new category of solutions from SAP’s partner ecosystem to help customers become best-run, intelligent enterprises. Endorsed apps are meant to deliver value with desired outcomes. “In the current economic climate, businesses are increasingly evaluating pricing software as a way to increase revenue and drive profit,” said Joe Golemba, Vice President, Ecosystem and Partners of Pricefx. “As such, we are delighted that our ODP solution is an SAP endorsed app and available to help businesses that use SAP solutions succeed at pricing. Our price optimization solution has helped many businesses transform data into insight to improve profitability, supporting our customers’ success.” SAP Endorsed Apps are premium certified by SAP with added security, in-depth testing and
IFF to Webcast Fireside Chat at Stifel Virtual Cross Sector Insight Conference June 82.6.2020 23:15:00 EEST | Press release
Regulatory News: IFF (NYSE:IFF) (Euronext Paris: IFF) (TASE: IFF), a leading innovator of taste, scent and nutrition, today announced that the Company’s management will be participating in a fireside chat at the Stifel Virtual Cross Sector Insight Conference on Monday, June 8, 2020 at 4:00 PM ET. Investors may access the live webcast on the Company's website at ir.iff.com. For those unable to listen to the live webcast, a recorded version will be made available for replay. Welcome to IFF At IFF (NYSE:IFF) (Euronext Paris: IFF) (TASE: IFF), we’re using Uncommon Sense to create what the world needs. As a collective of unconventional thinkers and creators, we put science and artistry to work to create unique and unexpected scents, tastes, experiences and ingredients for the products our world craves. Learn more at iff.com, Twitter , Facebook, Instagram, and LinkedIn. View source version on businesswire.com: https://www.businesswire.com/news/home/20200602005897/en/ Contact information Mich
Dr Evidence (DRE), an AI-Enabled SaaS Healthcare Insights Company, Taps Industry Experts Joseph A. Boystak as Chairman of the Board and Ameet Nathwani, MD, as Chairman of its Newly Formed Medical Strategy Advisory Board2.6.2020 17:00:00 EEST | Press release
DRE is pleased to welcome Joe Boystak as Chairman of the Board and Ameet Nathwani, MD, as Chairman of its newly formed Medical Strategy Advisory Board (MSAB). These enhancements to the Company reflect the expanded need for keen guidance in this unprecedented time of convergence between expert AI-enabled technology in healthcare and the exponential growth of clinical information. DRE is dedicated to applying sophisticated data science with advanced AI to generate quicker, deeper, more nuanced regulatory-grade scientific and clinical insights for the betterment of patient outcomes. Boystak is an experienced healthcare venture capitalist and senior healthcare investment banker having been Founding Managing Partner at Health2047 Capital Partners and Founding Managing Director, Global Life Sciences at Jefferies. He is CEO of Brightwaters Capital and is a serial co-founder/investor in biomedical, med tech, health information technology, and artificial intelligence companies with spinouts fro
ZOOM International to Begin Doing Business As Elevēo2.6.2020 17:00:00 EEST | Press release
ZOOM International a worldwide leader in omni-channel compliance recording, workforce optimization (WFO), and revenue protection software for contact centers will begin doing business solely as elevēo beginning June 2nd, 2020. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200602005093/en/ For over 20 years, ZOOM International has been a leading workforce optimization software provider in the contact center industry. Very early on, we were approached to solve a compliance problem with call recording. We built a creative software solution in record time, and began a journey crossing continents, employing hundreds of colleagues, and eventually improving operations, compliance, and customer experience for thousands of customers in 94 countries via more than 550 channel partners in the communications industry. Over time we have earned an 88 NPS score from ZOOM International customers & partners for our world-class support and in
Andersen Global Expands Presence in Qatar2.6.2020 16:30:00 EEST | Press release
Andersen Global announced its collaboration with Doha-based tax firm MS Partner, adding depth to the organization’s presence in Qatar and expanding its global platform. MS Partner was founded in 2018 and includes two Partners and more than 10 professionals that specialize in providing tax services to a variety of international clients including individuals and companies – both private and public. MS Partner’s Chairman His Excellency Shaikh Sultan Bin Jassim Bin Mohammed Al Thani is a prominent business leader in the State of Qatar. “We value our clients and people, and maintain the highest of professional standards,” said Office Managing Director Manikandan Rajan. “We’ve watched Andersen Global grow regionally as well as globally, and the organization has set the standard for providing clients with best-in-class service in an independent and seamless manner. We look forward to working closely with our fellow collaborating firm in Doha, Al-Khalifa Law, as well as all the collaborating f
Pegasus Development AG: Pegasus Present Its New Brand Pegastril - Nuevo2.6.2020 16:06:00 EEST | Press release
The coronavirus pandemic harbours the potential for enormous growth in specific industries. To that end, however, it's important to identify which markets will be dominant in the future. One of the key growth sectors is the production and distribution of disinfectants and associated technologies. Regardless of whether a cure for, or vaccine against, COVID-19 is developed, protection against viruses and bacteria has become incredibly important across the globe and will continue to be a concern going forward. This was one of the reasons why Pegasus Development AG decided to partner with the British disinfectant manufacturer Nuevo. One of the decisive factors choosing Nuevo was its highly competitive product, which is free from alcohol, animal products, perfume, essential oils or dyes. Furthermore, the product has already been tested according to the highest stipulations of the European standard EN 1276, is manufactured according to the latest regulations of the European Biocides Directiv
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom